Rapid adoption of Veeva Commercial Cloud continues across industry
for better multichannel customer engagement and greater commercial
efficiency
PHILADELPHIA--(BUSINESS WIRE)--
2017 Veeva Global Commercial & Medical Summit — Veeva
Systems (NYSE: VEEV) announced today that Bristol-Myers Squibb, a
global biopharmaceutical company, will expand its adoption of Veeva
Commercial Cloud in key markets outside of the U.S. The company will
add Veeva
CRM Events Management to better manage field events by streamlining
approvals and reducing complexity in the process. Bristol-Myers Squibb
will also leverage Veeva
CRM Approved Email to support an integrated, tailored customer
engagement experience.
Bristol-Myers Squibb is one of 22 life sciences companies that have
adopted Veeva CRM Events Management since its release, quickly
establishing it as a leading choice for companies to better orchestrate
their customer engagement strategies.
“Customers continue to turn to Veeva for a unified suite of applications
and data that deliver an orchestrated customer experience,” said Peter
Gassner, founder and CEO of Veeva. “We’re excited to expand our
relationship with Bristol-Myers Squibb and for the opportunity to
further support the company’s mission to discover, develop, and deliver
innovative medicines that help patients prevail over serious diseases.”
Veeva Commercial Cloud brings together customer data, compliant content,
and multichannel engagement to eliminate commercial complexity and speed
time to market. Life sciences companies use Veeva Commercial Cloud to
deliver greater agility, better customer engagement, and improved
efficiency throughout their commercial operations.
Additional Information
For more on Veeva Commercial Cloud, visit: veeva.com/CommercialCloud
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 500 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005992/en/
Source: Veeva Systems Inc.